AR063712A1 - Tratamiento del dolor usando satraplatino - Google Patents

Tratamiento del dolor usando satraplatino

Info

Publication number
AR063712A1
AR063712A1 ARP070104208A ARP070104208A AR063712A1 AR 063712 A1 AR063712 A1 AR 063712A1 AR P070104208 A ARP070104208 A AR P070104208A AR P070104208 A ARP070104208 A AR P070104208A AR 063712 A1 AR063712 A1 AR 063712A1
Authority
AR
Argentina
Prior art keywords
satraplatin
administration
prostate cancer
hormone
pain
Prior art date
Application number
ARP070104208A
Other languages
English (en)
Spanish (es)
Inventor
Marcel Rozencweig
Thomas Mckeam
Original Assignee
Gpc Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gpc Biotech Ag filed Critical Gpc Biotech Ag
Publication of AR063712A1 publication Critical patent/AR063712A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP070104208A 2006-09-24 2007-09-24 Tratamiento del dolor usando satraplatino AR063712A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84694206P 2006-09-24 2006-09-24
US90301407P 2007-02-22 2007-02-22
US90318107P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
AR063712A1 true AR063712A1 (es) 2009-02-11

Family

ID=38577465

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104208A AR063712A1 (es) 2006-09-24 2007-09-24 Tratamiento del dolor usando satraplatino

Country Status (6)

Country Link
US (1) US20090325913A1 (OSRAM)
EP (2) EP1905437A1 (OSRAM)
JP (1) JP2010504910A (OSRAM)
AR (1) AR063712A1 (OSRAM)
TW (1) TW200820982A (OSRAM)
WO (1) WO2008034910A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905439A1 (en) * 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
CN104984356A (zh) * 2015-05-14 2015-10-21 昆明贵研药业有限公司 赛特铂的环糊精复合物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397924T1 (de) * 2004-02-18 2008-07-15 Gpc Biotech Ag Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ES2327421T3 (es) * 2005-03-11 2009-10-29 Gpc Biotech Ag Terapia antiproliferativa combinada que comprende satraplatino o jm118 y docetaxel.
EP1905439A1 (en) * 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin

Also Published As

Publication number Publication date
JP2010504910A (ja) 2010-02-18
EP1905437A1 (en) 2008-04-02
TW200820982A (en) 2008-05-16
WO2008034910A1 (en) 2008-03-27
EP2066315A1 (en) 2009-06-10
US20090325913A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
MX2022006258A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
MY144043A (en) A pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
IN2012DN00827A (OSRAM)
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
WO2017091767A3 (en) Drug formulations for cancer treatment
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX2007000117A (es) Una composicion de combinacion.
WO2009012472A3 (en) Methods and compositions for treating conditions
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR062960A1 (es) Producto farmaceutico que comprende una composicion farmaceutica que incluye satraplatino para el tratamiento del cancer de prostata metastasico refractario a hormonas y usos del mismo
AR063712A1 (es) Tratamiento del dolor usando satraplatino
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BRPI0418801A (pt) métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit

Legal Events

Date Code Title Description
FB Suspension of granting procedure